All these efforts could significantly contribute to identifying new therapeutic targets and improving the management of patients with unexplained thrombosis and thrombocytopenia, including those who test negative for anti-PF4 antibodies, and may help to prevent thrombotic complications related to the use of adenoviral vector platforms for gene therapies through HLA-typing of candidate subjects. The gene discussed is PF4; the disease is deep vein thrombosis.